A practical reference on freeze-thaw cycling: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-09-06. Anything still debated is marked as such rather than presented as settled.
The molecule is a short, linear, hydrophilic peptide that dissolves readily in water or aqueous buffer. Its principal chemical liabilities are hydrolytic rather than oxidative, since it contains no cysteine, methionine, or tryptophan residues. The aspartate–glycine step is a recognised site for aspartimide formation under mildly acidic or basic conditions, generating isoaspartate and succinimide-related products over time. Desiccated lyophilised powder held at −20 °C is comparatively stable, whereas dilute solutions degrade faster and are best frozen as single-use aliquots rather than thawed repeatedly.
No pharmacopoeial monograph exists for this peptide, so quality rests on the supplier's internal specifications and on whatever independent testing a purchaser arranges. Certificates of analysis differ widely in which tests they report and in the limits applied. The counter-ion introduced during purification, commonly acetate or trifluoroacetate, changes the net peptide content of a given mass of powder, so two samples of equal weight may not contain equal amounts of the active sequence. Third-party laboratories can verify purity, identity, residual solvents, and counter-ion content for a fee, which makes documentation more informative than labelling.
Chemically, the molecule consists of four amino acid residues joined by three peptide bonds, with a free N-terminal amino group and a free C-terminal carboxyl group. Its molecular formula is C14H22N4O9, and its monoisotopic mass is approximately 390 daltons. The acidic glutamate and aspartate side chains give the peptide a net negative charge near neutral pH, a property that shapes its chromatographic behaviour and solubility profile. No disulfide bridges or other post-translational modifications are present, so the primary sequence alone defines the structure.
Most experimental work has been carried out in cell culture and animal models. Several reports describe changes in telomerase activity and proliferation in cultured cells, while rodent studies have examined lifespan, melatonin rhythm and reproductive endpoints. Human data remain limited, and much of the published clinical material consists of small trials with incomplete reporting of methods and controls. Whether the cell and animal findings translate into measurable effects in people is an open question, and the mechanistic basis of the reported telomerase changes is not fully established.
| Property | Value | Notes |
|---|---|---|
| Identity confirmation | Electrospray or MALDI mass spectrometry | Observed mass compared with theoretical 390.35 Da |
| Purity specification | 95 percent or greater by RP-HPLC | Common convention for research-grade peptide |
| Counter-ion | Acetate or trifluoroacetate | Affects net peptide content of a weighed sample |
| Solution storage | −80 °C as single-use aliquots | Repeated freeze–thaw cycles accelerate loss |
| Main degradation route | Aspartimide formation at Asp-Gly | Produces isoaspartate and related species |
Solubility is high in water, phosphate-buffered saline and normal saline, a pattern that follows from the two acidic residues in the chain. The peptide dissolves poorly in non-polar solvents such as hexane or chloroform. Stock solutions are often prepared in water first and then diluted into the buffer of interest. Because the molecule is small and hydrophilic, filtration through a low-protein-binding membrane is usually straightforward, and visible particulates are uncommon in freshly made solutions.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. The chromatogram shows the main peak and any truncated or oxidised by-products, while the mass spectrum confirms the expected 390 dalton mass. Amino acid analysis can corroborate composition when a sample's origin is uncertain. Counterion content, particularly residual trifluoroacetate from purification, is frequently reported alongside purity because it shifts the net mass of the solid.
Reference material is normally supplied as a lyophilised powder in a sealed vial. Product literature typically recommends storage at minus twenty degrees Celsius or colder, protected from light and moisture. Freeze-thaw cycling is usually avoided because repeated condensation can introduce water into the vial. Working solutions are commonly prepared fresh, aliquoted, and kept cold for short periods rather than stored at ambient temperature. Labelling the date of opening helps track how long a vial has been in use.
Published studies on epitalon are dominated by a small number of research groups, and independent replication in other laboratories remains limited. Proposed mechanisms include activation of telomerase and modulation of melatonin rhythms, but the evidence for either rests mainly on cell cultures and animal models. Whether the peptide produces comparable effects in humans is an open question, and the absence of large controlled trials means the literature is best read as exploratory rather than settled.
Epitalon is a synthetic four-amino-acid peptide with the sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its molecular formula is C14H22N4O9, and its calculated molar mass is approximately 390.35 grams per mole. The compound is a short fragment related to a peptide fraction isolated from bovine pineal gland extracts, and it is normally supplied as a lyophilised powder intended for laboratory research. It is not a registered pharmaceutical product in most countries.
The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection, frequently near 214 nanometers where the peptide bond absorbs. Mass spectrometry, most often with electrospray ionization, confirms the observed molecular mass and helps separate the intact peptide from truncated or modified forms. Amino acid analysis or tandem mass spectrometry can establish residue order. Purity is commonly quoted as an area percentage, yet such values are method-dependent, and comparisons between laboratories require matching column, gradient and detection wavelength.
Laboratory handling begins with dissolution of the lyophilized powder in water or a suitable aqueous buffer. The dry solid is the more stable form, so stock solutions are generally prepared only when required and kept cold afterwards. Repeated freezing and thawing of a solution is avoided because it encourages aggregation and gradual loss of the intact chain. Diluents and containers are selected to limit adsorption of a short peptide onto plastic surfaces and to reduce microbial growth in aqueous preparations.
Prior to the Air Pollution Control Act of 1955, little headway was made to initiate this air pollution reform. U.S. cities Chicago and Cincinnati first established smoke ordinances in 1881. In 1904, Philadelphia passed an ordinance limiting the amount of smoke in flues, chimneys, and open spaces. The ordinance imposed a penalty if not all smoke inspections were passed. It was not until 1947 that California authorized the creation of Air Pollution Control Districts in every county of the state.
=== Fission product === In contrast to the rare natural occurrence, bulk quantities of technetium-99 are produced each year from spent nuclear fuel rods, which contain various fission products. The fission of a gram of uranium-235 in nuclear reactors yields 27 mg of technetium-99, giving technetium a fission product yield of 6.1%. Other fissile isotopes produce similar yields of technetium, such as 4.9% from uranium-233 and 6.21% from plutonium-239. An estimated 49,000 TBq (78 metric tons) of technetium was produced in nuclear reactors between 1983 and 1994, by far the dominant source of terrestrial technetium. Only a fraction of the production is used commercially. Technetium-99 is produced by the nuclear fission of both uranium-235 and plutonium-239. It is therefore present in radioactive waste and in the nuclear fallout of fission bomb explosions. Its decay, measured in becquerels per amount of spent fuel, is the dominant contributor to nuclear waste radioactivity after about 104–106 years after the creation of the nuclear waste. From 1945 to 1994, an estimated 160 TBq (about 250 kg) of technetium-99 was released into the environment during atmospheric nuclear tests. The amount of technetium-99 from nuclear reactors released into the environment up to 1986 is on the order of 1000 TBq (about 1600 kg), primarily by nuclear fuel reprocessing; most of this was discharged into the sea.
Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983. Repaglinide is a medication used in addition to diet and exercise for blood sugar control in type 2 diabetes. The mechanism of action of repaglinide involves promoting insulin release from β-islet cells of the pancreas; like other antidiabetic drugs, a main side effect concern is hypoglycemia. It is sold by Novo Nordisk under the name of Prandin in the United States, Gluconorm in Canada, Surepost in Japan, Repaglinide in Egypt, and Novonorm elsewhere. In Japan it is produced by Dainippon Sumitomo Pharma.
Sources: en.wikipedia.org
The Chanka people lived in the Huancavelica, Ayacucho, and Apurímac regions of Peru. The Huanca people of the Junín Region of Peru spoke Quechua before the Incas did. The Inca established the largest empire of the pre-Columbian era. The Chincha, an extinct merchant kingdom of the Chincha Islands of Peru. The Qolla inhabited the Potosí, Oruro, and La Paz departments of Bolivia. The Cañari of Ecuador adopted the Quechua language from the Inca. The speakers of Quechua total some 5.1 million people in Peru, 1.8 million in Bolivia, 2.5 million in Ecuador (Hornberger and King, 2001), and according to Ethnologue (2006) 33,800 in Chile, 55,500 in Argentina, and a few hundred in Brazil. Only a slight sense of common identity exists among these speakers spread all over Peru, Bolivia and Ecuador. The various Quechua dialects are in some cases so different from one another that mutual understanding is not possible. Quechua was spoken not only by the Incas, but also by long-term enemies of the Inca Empire, including the Huanca (Wanka is a Quechua dialect spoken today in the Huancayo area) and the Chanka (the Chanca dialect of Ayacucho) of Peru, and the Kañari (Cañari) in Ecuador. Quechua was spoken by some of these people, for example, the Wanka, before the Incas of Cusco, while other people, especially in Bolivia but also in Ecuador, adopted Quechua only in Inca times or afterward. Some Christian organizations also refer to a "Quechua people", such as the Christian shortwave radio station HCJB, "The Voice of the Andes" (La Voz de los Andes).
These analogues were studied for neurodegenerative diseases, demonstrating improved stability and brain penetration, strong binding affinity to the targeted receptors, and positive effects on cognitive function and neuroprotection in animal models. IRAP inhibitors have also been found to counteract acetylcholine-induced vasoconstriction in vivo, highlighting IRAP's role in modulating vascular function. IRAP deletion reduces susceptibility to pentylenetetrazol-induced seizures in mice, suggesting its potential as epilepsy therapeutic target. IRAP plays an important role in the regulation of the immune system. Similarly to ERAP1 and ERAP2, IRAP is able to trim the N-terminal of antigenic peptides, reducing their length to 8-10 amino acids, the optimal length for MHC class I binding. In contrast to ERAP1 and ERAP2, there is no evidence of IRAP-mediated trimming of antigenic peptides in the endoplasmic reticulum for the MHC-I presentation through the direct pathway. On the other hand, IRAP has a primary function in cross-presentation. Here, the aminopeptidase trims cross-presented peptides in a specific endosomal compartment, described in dendritic cells, before their loading on IRAP-associated MHC class I molecules. IRAP stabilizes the particular type of regulated early endosomes it is located in. The stability of these endosomes is essential for the cross-presentation pathway in dendritic cells, and regulates several endosomal signaling pathways (TCR, TLR9, TNFα, IL-6) in other immune cell types.
==== Androgen receptor ==== Although it functions as an endogenous precursor to more potent androgens such as testosterone and DHT, DHEA has been found to possess some degree of androgenic activity in its own right, acting as a low affinity (Ki = 1 μM), weak partial agonist of the androgen receptor (AR). However, its intrinsic activity at the receptor is quite weak, and on account of that, due to competition for binding with full agonists like testosterone, it can actually behave more like an antagonist depending on circulating testosterone and dihydrotestosterone (DHT) levels, and hence, like an antiandrogen. However, its affinity for the receptor is very low, and for that reason, is unlikely to be of much significance under normal circumstances.
The Litton detector was developed for sampling the light energy distribution in the rear focal-plane of a spherical lens for sampling geometric relationships and the spectral density distribution of objects recorded on film transparencies. The application of the Litton detector by Salzman et al. provided measurement at 32 small scattering angles between 0° and 30°, and averaging over a broad range of azimuthal angles as the most important angles are the forward angles for static light scattering. By 1980, Bartholi et al. had developed a new approach to measuring the scattering at discrete scattering angles by using an elliptical reflector to permit measurement at 30 polar angles over the range 2.5° ≤ θ ≤ 177.5° with a resolution of 2.1°. The commercialization of multiangle systems began in 1977 when Science Spectrum, Inc. patented a flow-through capillary system for a customized bioassay system developed for the USFDA. The first commercial MALS instrument incorporating 8 discrete detectors was delivered to S.C. Johnson and Son, by Wyatt Technology Company, in 1983, followed in 1984 with the sale of the first 15 detector flow instrument (Dawn-F) to AMOCO. By 1988, a three-dimensional configuration was introduced specifically to measure the scattering properties of single aerosol particles. At about the same time, the underwater device was built to measure the scattered light properties of single phytoplankton. Signals were collected by optical fibers and transmitted to individual photomultipliers.
Sources: en.wikipedia.org
== Uses == Polymersomes that contain active enzymes and that provide a way to selectively transport substrates for conversion by those enzymes have been described as nanoreactors. Polymersomes have been used to create controlled release drug delivery systems. Similar to coating liposomes with polyethylene glycol, polymersomes can be made invisible to the immune system if the hydrophilic block consists of polyethylene glycol. Their permeability can be modulated by exogenous factors, for example by incorporation of stimuli-responsive molecules such as photoswitches, or pH responsive groups. Thus, polymersomes are useful carriers for targeted drug delivery. For in vivo applications, polymersomes are de facto limited to the use of FDA-approved polymers, as most pharmaceutical firms are unlikely to develop novel polymers due to cost issues. Fortunately, there are a number of such polymers available, with varying properties, including: Hydrophilic blocks
1 August A meta-analysis of policy studies concludes that international treaties that aim to foster global cooperation have mostly failed to produce their intended effects in addressing global challenges, with the exception of international trade and finance regulations. The study suggests enforcement mechanisms are the "only modifiable treaty design choice" with the potential to improve the effectiveness. The discovery of a super-Earth around the red dwarf star Ross 508 is reported. Part of the planet's elliptical orbit takes it within the habitable zone. Researchers report that the risk of climate change (indirectly) resulting in worldwide societal collapse, or possibly eventual human extinction, is a "dangerously underexplored" global topic, despite there being indications of such being possible as worst-case scenarios and "integrated catastrophe assessment" missing. Israeli researchers report the achievement of first stem-cell derived synthetic embryos, which are "organ-filled" and were grown solely from mouse embryonic stem cells, without sperm or eggs or a uterus, with natural-like development and some surviving until day 8.5 where early organogenesis, including formation of foundations of a brain, occurs. They grew in vitro and subsequently ex utero in an artificial womb devised in the year before by the same team. 2 August Scientists conclude that the overall transgressed (see 18 January) planetary boundary for "novel entities" (NEs) is a placeholder for multiple different boundaries for NEs that may emerge, reporting that PFAS pollution is one such new boundary.
== University of Toronto == Despite its initial reservations centred upon Robertson's apparent "commercial leanings" (and, specifically, his decision to patent "tethelin"), and following "an unusually careful review process", the University of Toronto appointed Robertson as Professor in the Department of Biochemistry in 1918. He moved to Toronto, accompanied by Hardolph Wasteneys, who later became the head of the Toronto Department from 1929 to 1951. Robertson resigned in 1919, in order to take up his position at the University of Adelaide, and was succeeded, at Toronto, by Professor Andrew Hunter, C.B.E., F.R.S.C., F.R.S.E. (1876–1969).
Gram Parsons died from a drug and alcohol overdose on September 19, 1973. He was 26 years old. In the late 1960s, Parsons began to vacation at Joshua Tree National Monument in southeastern California, where he used psychedelics and said he experienced UFO sightings. After splitting from Burrell, Parsons often spent his weekends there with Margaret Fisher and Phil Kaufman. Scheduled to resume touring in October 1973, Parsons decided to go on another recuperative excursion on September 17. Accompanying him were Fisher, his assistant Michael Martin, and Martin's girlfriend Dale McElroy. On both nights of their stay, Parsons retreated to the desert, consuming large amounts of alcohol and barbiturates, while the rest of the group visited bars in nearby Yucca Valley. On September 18, Martin drove back to Los Angeles to resupply the group with marijuana. That night, Parsons challenged Fisher and McElroy to drink with him; Fisher did not drink and McElroy was recovering from illness. Parsons said that he would drink for the three of them and drank six double tequilas. The three then went to the Joshua Tree Inn, where Parsons purchased morphine from an unknown woman; after being injected by her in Room No. 1, he overdosed. Fisher gave Parsons an ice cube suppository, and then a cold shower and moved him to Room No. 8. She put him to bed and went out to buy coffee in the hope of reviving him, leaving McElroy to stand guard. As his breathing became irregular and then ceased, McElroy attempted resuscitation. After all attempts failed, they called an ambulance.
=== Phase III - further modification and excretion === After phase II reactions, the xenobiotic conjugates may be further metabolised. A common example is the processing of glutathione conjugates to acetylcysteine (mercapturic acid) conjugates. Here, the γ-glutamate and glycine residues in the glutathione molecule are removed by Gamma-glutamyl transpeptidase and dipeptidases. In the final step, the cystine residue in the conjugate is acetylated. Conjugates and their metabolites can be excreted from cells in phase III of their metabolism, with the anionic groups acting as affinity tags for a variety of membrane transporters of the multidrug resistance protein (MRP) family. These proteins are members of the family of ATP-binding cassette transporters and can catalyse the ATP-dependent transport of a huge variety of hydrophobic anions, and thus act to remove phase II products to the extracellular medium, where they may be further metabolised or excreted.
Sources: en.wikipedia.org
Mass spectrometry provides the identity check, because the observed mass is compared with the theoretical mass of the AEDG sequence. Chromatography separates and quantifies impurities but does not by itself prove which peptide is present. The two techniques are normally used together.
Yes. Trifluoroacetate and acetate ions remain associated with the peptide after purification, so a weighed quantity of powder contains less peptide than the nominal mass suggests. Certificates that report net peptide content rather than raw weight are more directly comparable between suppliers.
Dilute aqueous solutions are less stable than the dry powder and are usually aliquoted and frozen to avoid repeated freeze–thaw cycles. Lyophilised material is best stored desiccated at −20 °C, protected from light. Working solutions are typically prepared fresh from a frozen aliquot.
It is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, often abbreviated AEDG. The molecule is linear and contains no modified residues, so it is fully described by its sequence.